NEW YORK (GenomeWeb) – Following publication of a landmark study involving Tesaro's PARP inhibitor niraparib and Myriad Genetics' myChoice HRD test, Myriad's stock tumbled around 12 percent in Monday afternoon trading.

This past weekend, researchers led by Mansoor Mirza of Copenhagen University Hospital in Denmark presented data from the NOVA trial at a European oncology conference, which compared Tesaro's PARP inhibitor niraparib against placebo in 553 patients with recurrent ovarian cancer who had responded to platinum-based chemotherapy.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Jan
30
Sponsored by
Loop Genomics

This webinar will provide a comparison of several next-generation sequencing (NGS) approaches — including short-read 16S, whole-genome sequencing (WGS), and synthetic long-read sequencing technology — for use in microbiome research studies.

Jan
30
Sponsored by
Loop Genomics

This webinar will provide a comparison of several next-generation sequencing (NGS) approaches — including short-read 16S, whole-genome sequencing (WGS), and synthetic long-read sequencing technology — for use in microbiome research studies.